Broadcast Date: 
  • Time: 

Gene therapy has undergone a renaissance in recent years, with several drugs offering beneficial, even life-saving treatments, now approved by the FDA. One example was reported earlier this year, with the progress made by two separate research teams working on gene therapy programs targeting hearing loss. And the FDA has stated that they expect an increase in the number of authorizations of gene therapy treatments over the next few years. But getting gene therapies into patients is a challenging road.

On this episode of GEN Live, we will discuss the state of gene therapy today, the promises and pitfalls of delivery vectors, the challenge posed by the immune response, and the safety issues that need to be addressed going forward. Dr. Federico Mingozzi, who has been working in the gene therapy field for over two decades, joins Dr. Allison May Keeler-Klunk, assistant professor at UMass Chan Medical School, to share their perspectives on the field’s current progress and future challenges.

A live Q&A session followed the presentation, offering a chance to pose questions to our expert panelists.

Federico Mingozzi, PhD,
Federico Mingozzi, PhD
Former CSO and CTO
Formerly Spark Therapeutics
Allison May Keeler-Klunk, PhD
Allison May Keeler-Klunk, PhD
Assistant Professor
UMass Chan Medical School